Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,…
Browsing Tag